Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)

Trial Profile

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs KW 2449 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Kyowa Kirin Pharmaceutical Development
  • Most Recent Events

    • 04 Apr 2008 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 23 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top